A Phase 1 Study of LY2835219 In Participants With Advanced Cancer

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

225 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-12-07

Study Completion Date

2022-04-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine a safe dose of Abemaciclib to be given to participants with advanced cancer and to determine any side effects that may be associated with Abemaciclib in this population. Efficacy measures will be used to assess the activity of Abemaciclib in this population.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

NCT04031885

Metastatic Breast Cancer

TERMINATED PHASE4

A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer

NCT02107703

Breast Neoplasms

ACTIVE_NOT_RECRUITING PHASE3

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

NCT02057133

Breast Neoplasms

ACTIVE_NOT_RECRUITING PHASE1

A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer

NCT02763566

Breast Cancer

ACTIVE_NOT_RECRUITING PHASE3

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Therapies in Japanese Participants With Advanced Cancer

NCT04071262

Advanced Cancer

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Abemaciclib

Participants received oral Abemaciclib administered on Days 1 through 28 of a 28-day cycle except in Cycle 1, where the study drug was administered as appropriate on Day -3 and then on Days 1 to 27. The treatment was continued until a discontinuation criterion was met or under Sponsor's discretion.

Participants belonging to different Parts received the study drug as specified below:

Part A: 50 mg/100 mg/150 mg/225 mg every 24 hours (Q24H) or 75mg/100 mg/150 mg/200 mg/275 mg every 12 hours (Q12H).

Parts B, C, D, and E: 150 mg/200 mg Q12H. Part F: 150 mg Q12H. Part G: 200 mg Q12H along with 500 mg Fulvestrant administered intramuscularly.

Group Type EXPERIMENTAL

Abemaciclib

Intervention Type DRUG

Administered orally.

Fulvestrant

Intervention Type DRUG

Fulvestrant is administered intramuscularly into the buttocks in Part G only.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Abemaciclib

Administered orally.

Intervention Type DRUG

Fulvestrant

Fulvestrant is administered intramuscularly into the buttocks in Part G only.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

LY2835219

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* For all Parts (Dose escalation and expansion): The participant must be, in the judgment of the investigator, an appropriate candidate for experimental therapy either after available standard therapies have ceased to provide clinical benefit (Parts A, B, C, D, E and F) or in combination with fulvestrant (Part G only)
* For Dose Escalation (Part A): The participant must have histological or cytological evidence of cancer, either a solid tumor or a lymphoma, which is advanced and/or metastatic
* For Dose Expansion (Parts B, C, D, E, F and G): The participant must have histological or cytological evidence of one of the following cancers:

* Part B: Non-small cell lung cancer of any subtype that is advanced and/or metastatic
* Part C: Glioblastoma multiforme that has progressed or recurred after radiotherapy and/or chemotherapy
* Part D: Breast cancer that is advanced and/or metastatic
* Part E: Melanoma that is advanced and/or metastatic
* Part F: Colorectal Cancer
* Part G: Breast Cancer that is not only advanced and/or metastatic but also hormone receptor positive
* As defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) or the Revised Response Criteria for Malignant Lymphoma

* For Parts A and G: Have measurable or nonmeasurable disease
* For Parts B, C, D, E and F: Have measurable disease
* Have given written informed consent prior to any study-specific procedures
* Have adequate hematologic, hepatic, and renal function
* Have a performance status less than or equal to 1 for Dose Escalation (Part A) and less than or equal to 2 for Dose Confirmation (Parts B, C, D, E, F and G) on the Eastern Cooperative Oncology Group (ECOG) scale
* Have discontinued all previous therapies for cancer (including chemotherapy, radiotherapy, immunotherapy, and investigational therapy) with the exception of fulvestrant (for Part G only) for at least 21 days for myelosuppressive agents or 14 days for nonmyelosuppressive agents prior to receiving study drug, and recovered from the acute effects of therapy (treatment related toxicity resolved to baseline) except for residual alopecia
* Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures
* Males and females with reproductive potential must agree to use medically approved contraceptive precautions during the trial and for 3 months following the last dose of study drug
* Females with child bearing potential must have a negative serum pregnancy test within 3 days of the first dose of study drug
* Have an estimated life expectancy of greater than or equal to 12 weeks
* Are able to swallow capsules

Exclusion Criteria

* Have received treatment with a drug that has not received regulatory approval for any indication within 14 or 21 days of the initial dose of study drug for a nonmyelosuppressive or myelosuppressive agent, respectively
* Have a personal history of any of the following conditions: presyncope or syncope of either unexplained or cardiovascular etiology, ventricular arrhythmia (including but not limited to ventricular tachycardia and ventricular fibrillation), sudden cardiac death or sudden cardiac arrest
* Have serious preexisting medical conditions that, in the judgment of the investigator, would preclude participation in this study (for example, history of major surgical resection involving the stomach or small bowel)
* For Dose Escalation (Part A): Have central nervous system (CNS) malignancy or metastasis
* For Dose Confirmation (Parts B, D, E, F and G): Have CNS metastasis that is radiographically or clinically unstable less than 14 days prior to receiving study drug, regardless of whether they are receiving corticosteroids
* For Dose Confirmation (Part C): Have glioblastoma multiforme that is radiographically or clinically unstable less than 14 days prior to receiving study drug, regardless of whether they are receiving corticosteroids
* Have an acute leukemia
* Have received an autologous or allogeneic stem-cell transplant within 75 days of the initial dose of study drug
* Females who are pregnant or lactating
* Have active bacterial, fungal, and/or known viral infection (for example, human immunodeficiency virus \[HIV\] antibodies, hepatitis B surface antigen \[HBSAg\], or hepatitis C antibodies) Screening is not required for enrollment

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No